A Phase II/III Study to Evaluate the Efficacy and Safety of MR19A13A in Pediatric Patients.

obuyo Oya0 sites72 target enrollmentOctober 27, 2022

Overview

No summary available.

Registry

who.int

Start Date

October 27, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

obuyo Oya

•1\) Japanese Patients aged from 6 months to 16 years, at the time of informed consent.
•2\) Patients with written consent from their legal representatives; If the patient is over 7 years, it is desirable to obtain the assent also from the patient as possible.

•1\) Patients with the history of hypersensitivity or suspected hypersensitivity to any ingredients of the study drug.
•2\) Patients with acute angle\-closure glaucoma.
•3\) Patients with myasthenia gravis.
•4\) Patients receiving the drug containing HIV protease inhibitors, efavirenz, or cobicistat.
•5\) Patients receiving St. John's wort supplement and are unable to discontinue taking the supplement from 1 week prior to the start of study drug administration up to 8 hours after the completion of study drug administration.
•6\) Patients with moderate to severe cerebral palsy.
•7\) Patients with other central nervous system disorders including poorly controlled convulsive disorders, spasm within 1 week prior to the day of administration, a history or possible history of increased intracranial pressure, or known psychiatric disorders that may exacerbate normal response to sedative medications (Patients who have had one episode of febrile convulsion in the past will not be excluded).
•8\) Patients using or expected to use artificial heart\-lungs during the surgery.
•9\) Patients expected to receive blood transfusion during or after the surgery (up to 8 hours after completion of the study drug administration).
•10\) Patients who have received the drug that may interfere with sedation evaluation within 8 hours prior to the start of study drug administration.